CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced ...
To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel has been observed to be well tolerated. The study included one Complete Response out of ...
QUEBEC CITY and SYDNEY, Oct. 31, 2024 /CNW/ - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, ...
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback